IP Library Granted Patent US 8,840,905
Granted Patent B2
US 8,840,905 · App. 12/268,993 · Granted Sep 23, 2014

Use of neurotoxin therapy for treatment of urologic and related disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,840,905
App. No.
12/268,993
Granted
Sep 23, 2014
Kind
B2
Abstract

The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.

Claims (8)

1. A method for treating urinary incontinence in a patient having at least one symptom of urinary incontinence, the method comprising the step of administering a therapeutically effective amount of between 1.4 IU/kg to 17.1 IU/kg of botulinum toxin type A to the urinary tract of the patient, thereby treating at least one symptom of urinary incontinence in the patient.

2. The method of claim 1 , wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation selected from the group consisting of: a liquid, a powder, a cream, an emulsion, a pill, a troche, a suppository, a suspension, and a solution.

3. The method of claim 1 , wherein the botulinum toxin is administered to the patient as serial dosages.

4. The method of claim 1 , wherein the botulinum toxin type A is administered is to a bladder wall.

5. A method for treating a urinary incontinence disorder in a patient having at least one symptom of urinary incontinence, the method comprising injecting 200 units of a botulinum toxin type A to the bladder of the patient, thereby treating a symptom of urinary incontinence in the patient.

6. The method of claim 5 , wherein injection is to a bladder wall.

7. The method of claim 5 , wherein the botulinum toxin type A is a pharmaceutically acceptable formulation selected from the group consisting of a liquid, a suspension, and a solution.

8. The method of claim 5 , wherein the botulinum toxin type A is administered to the patient as serial dosages.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2015
From: THE REGENTS OF THE UNIVERSITY OF COLORADO
To: ALLERGAN, INC.
Reel/Frame 036260/0570 →